Archive — US — techcrunch
FDA approval, fundraising, and the reality of building in healthcare accordingto BioticsAI founder
BioticsAI's Robhy Bustami highlights the challenges of healthcare innovation, emphasizing the importance of rigorous integration of clinical validation and regulatory strategy. The company recently gained FDA approval for its AI ultrasound tool aimed at detecting fetal abnormalities, paving the way for deployment in hospitals and expansion into reproductive health.
Key points
- BioticsAI's AI copilot for ultrasound addresses high misdiagnosis rates in fetal abnormalities.
- The company developed its prototype for under $100,000, winning the TechCrunch Startup Battlefield in 2023.
- They secured FDA approval in January, allowing for hospital deployment.
- Early engagement with regulators and alignment across teams facilitated the product development process.
- Navigating long timelines and keeping team motivation are critical for sustained progress.
Why it matters
- The article reflects a trend in 2025 IT where healthcare startups must integrate regulation from the outset.
- The growth of AI in healthcare aligns with increasing demand for innovative solutions to reduce misdiagnosis.
- The emphasis on early engagement with regulators is similar to practices emerging in other heavily regulated industries.
BioticsAI exemplifies the strategic, patient-focused approach required in healthcare innovation, illustrating how founders can navigate regulatory complexities to achieve meaningful advancements in care delivery.